tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Moleculin Biotech reports Q3 EPS (30c) vs. (15c) a year ago

The company ended the quarter with $50.4M of cash. The company believes that this cash is sufficient to meet its projected operating requirements, which include a forecasted increase over its current R&D rate of expenditures, beyond mid-2024.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Disclaimer & DisclosureReport an Issue

1